AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

AbbVie Inc.'s next-generation combination therapy for hepatitis C, Mavyret (glecaprevir/pibrentasvir), will be the first eight-week regimen to treat all non-cirrhotic genotypes of the virus, narrowing the treatment window from what previously was 12 weeks. Marvyret could help AbbVie fill a gap left by declining sales of its first HCV combination Viekira Pak and challenge rival Gilead Sciences Inc.'s near-monopoly, particularly in genotypes 2 and 3 of the virus.

FDA announced the approval of Mavyret Aug. 3 to treat HCV virus genotypes 1-6 without cirrhosis or with mild cirrhosis including patients with moderate-to-severe kidney disease who are on dialysis. It is also approved for genotype 1 patients who might have failed prior treatment